We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Groundbreaking Genomics Method to Improve Early Detection of Genetic Diseases

By LabMedica International staff writers
Posted on 02 Dec 2024

Researchers using next-generation sequencing are uncovering valuable insights from the non-coding segments of human DNA, which were once considered "junk DNA. More...

" These segments, called non-coding RNAs, hold critical information on the presence of diseases. In a new approach, scientists are working to adapt laboratory equipment initially designed to analyze only mRNA, the coding parts of genetic material, and also examine the non-coding regions of DNA. This innovative genomics technique could reveal the genetic mechanisms behind both human health and diseases, offering a potential method for early detection of conditions like cancer and dementia. The research, published in Genome Biology, proposes a novel approach to exploring the root causes of various diseases.

Over the past two decades, researchers have used advanced tools to analyze non-coding RNAs and identify the 3% of sequences that are coded. As part of the Canadian Epitranscriptomics Project, scientists at the University of Manitoba (Winnipeg, Canada) are leveraging this technology to create the "Epitranscriptome Atlas," which aims to map the remaining 97% of the human genome. This effort will enhance our understanding of how alterations in non-coding RNAs contribute to disease.

“My lab applies what we call next-generation sequencing and bioinformatics to magnify the impact of recent advances in AI algorithms,” said Dr. Athanasios Zovoilis, associate professor of biochemistry and medical genetics in the Max Rady College of Medicine. “The right equipment for this new field of study has been in our lab for some time, but we lacked the tools to use it to its fullest potential, until now. The impact of employing AI and novel genomics approaches is that researchers across the world can now leverage next-generation sequencing in the new field of epitranscriptomics, exploring the genetic interactions of non-coding RNAs.”

“If we imagine the human genome as an atlas of the earth, with each gene represented by one satellite image, we have so far revealed fewer than 36,000 of the necessary 1.2 million images to complete our atlas. The mapped RNA sequences represent specific human tissues, and we are now able to begin filling in large sections of our atlas to pinpoint the genomic locations of diseases and other important biological functions for the first time,” Zovoilis added.

 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.